Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R01 in Advanced Solid Tumors
NCT07806500Phase 1Not yet recruiting
- Sponsor
- Beijing Anjianxi Pharmaceutical Technology
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R01 in squamous cell carcinoma of the lung (LSCC), gastric cancer (GC) and esophageal cancer, sponsored by Beijing Anjianxi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicities at 21 days, Maximum Tolerated Dose at 9 months and 2 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
R01
03
Conditions
squamous cell carcinoma of the lung (LSCC)gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT07806500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806500.